Scholarlink

<p>Among the various histological types of thyroid cancer (TC), papillary thyroid carcinoma (PTC) is highly prevalent. Studies conducted in the past have revealed that the LncRNA DLEU2 is aberrantly expressed in PTC and is relevant to tumorigenesis and lymphatic metastasis. There is still uncertainty about the function and underlying mechanisms of LncRNA DLEU2 in PTC cells. Our findings indicate that DLEU2 facilitates the migration and invasion of PTC cells. Analysis from the Starbase database demonstrated a positive interaction and relationship between the RNA-binding protein (RBP) ELAVL1 and DLEU2. Fluorescence co-localization and RIP assays confirmed the binding of DLEU2 and ELAVL1 within PTC cells. ELAVL1 was found to enhance the migration and invasion of PTC cells, as demonstrated by wound healing and Transwell invasion assays. ELAVL1 preferentially binds to and stabilizes m6A-modified mRNAs. Bioinformatic analysis, western blotting, and RT-qPCR results revealed that RCC2, a downstream target of ELAVL1, was regulated by ELAVL1. MeRIP and RNA stability assays showed that ELAVL1 modulates RCC2 mRNA stability through m6A modification. Through rescue experiments, the DLEU2-ELAVL1-RCC2 axis was identified in PTC cells, demonstrating its function in cell migration and invasion. Through the Wnt5a/β-catenin signaling pathway, this axis may support epithelial-mesenchymal transition (EMT) and enhance cellular migration and invasion. Collectively, our findings elucidate the functional mechanism of the DLEU2-ELAVL1-RCC2 axis in PTC cells and provide a possible molecular target for treating PTC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

DLEU2 promotes the migration and invasion of papillary thyroid carcinoma cells through the ELAVL1/RCC2 axis

  • 期刊论文

  • 发表日期：

    2026年6月16日

查看全文
  • Suwei Zuo,
  • Sinuo Sun,
  • Yuanyuan Wang,
  • Jiayin Song,
  • Yanmeng Zhou,
  • Shibo Liu,
  • Gang Xue,
  • Xu Lin,
  • Jing-fang Wu

摘要

Among the various histological types of thyroid cancer (TC), papillary thyroid carcinoma (PTC) is highly prevalent. Studies conducted in the past have revealed that the LncRNA DLEU2 is aberrantly expressed in PTC and is relevant to tumorigenesis and lymphatic metastasis. There is still uncertainty about the function and underlying mechanisms of LncRNA DLEU2 in PTC cells. Our findings indicate that DLEU2 facilitates the migration and invasion of PTC cells. Analysis from the Starbase database demonstrated a positive interaction and relationship between the RNA-binding protein (RBP) ELAVL1 and DLEU2. Fluorescence co-localization and RIP assays confirmed the binding of DLEU2 and ELAVL1 within PTC cells. ELAVL1 was found to enhance the migration and invasion of PTC cells, as demonstrated by wound healing and Transwell invasion assays. ELAVL1 preferentially binds to and stabilizes m6A-modified mRNAs. Bioinformatic analysis, western blotting, and RT-qPCR results revealed that RCC2, a downstream target of ELAVL1, was regulated by ELAVL1. MeRIP and RNA stability assays showed that ELAVL1 modulates RCC2 mRNA stability through m6A modification. Through rescue experiments, the DLEU2-ELAVL1-RCC2 axis was identified in PTC cells, demonstrating its function in cell migration and invasion. Through the Wnt5a/β-catenin signaling pathway, this axis may support epithelial-mesenchymal transition (EMT) and enhance cellular migration and invasion. Collectively, our findings elucidate the functional mechanism of the DLEU2-ELAVL1-RCC2 axis in PTC cells and provide a possible molecular target for treating PTC.